Fig. 6
co-treatment with NAC and PLZ inhibited subcutaneous tumor growth in the xenografted organoid model with PSC co-implantation. a Representative photomicrographs of cancer organoids derived from KPC mice. Scale bars = 100 μm. b Nude mice (n = 7/per group) were subcutaneously transplanted with KPC mouse-derived organoids (5 × 105) and mouse PSCs (5 × 105) into the flank. After 1 week, the mice were injected intraperitoneally with Gemcitabine (40 mg/kg, once a week, also named group2) or NAC (500 mg/kg) + PLZ (4 mg/kg) (twice a week, group3), or Control (100 μl PBS + 0.1 μl DMSO, twice a week, group1) for 4 weeks. Representative photograph showing significantly reduced tumor formation after 4 weeks of NAC + PLZ co-treatment. c Tumor volume was significantly decreased in GEM and NAC + PLZ co-treatment groups after 4 weeks of treatment. d The average weight of each group of mice. Also see supplementary figure S6.E for weight change of each mouse in each group. e H&E staining, Masson’s staining trichrome and immunohistochemical staining of α-SMA, CK19, PPARγ, HMOX-1, Nrf2 and PCNA. Original magnification, × 100. Scale bar = 100 μm. *P < 0.05; **P < 0.01; ***P < 0.001; n.s, no significance